Target Markets Poietis operates in health-tech and provides Next Generation Bioprinting (NGB) systems for Cell Therapy and Research Centers, with activity in translational medicine and Advanced Therapies. Potential sales opportunities include bioprinting system sales or upgrades to research institutions and clinical facilities pursuing ATMP manufacturing and cGMP-compliant workflows.

Strategic Partnerships Past partnerships with university and regulatory-adjacent centers (e.g., Universitat de Barcelona cGMP facility, Scintica distribution) indicate a receptiveness to channel partnerships and OEM/integration deals. Focus on expanding distribution networks, regional partners, or joint development agreements with biopharma and contract manufacturing organizations.

Expansion Signals Active participation in industry events such as TERMIS-EU 2026 suggests momentum and ongoing market engagement. Leverage event exposure to generate demo requests, accelerate early-adopter contracts, and position Poietis as a thought leader in 4D bioprinting for tissue manufacturing.

Global Reach Existing international partnerships (US, Australia, Europe) and multi-region interest imply a scalable sales approach through regional distributors and international sales teams. Opportunities exist to convert partnerships into formalized global sales, services, and training packages for installed bases.

Financial Readiness Funding of 6.2M and a modest revenue range indicate a growth-focused company likely seeking pilot programs, grant-supported deployments, and capital-efficient contracts. Propose phased deployments, rental or leasing options, and collaboration on ATMP manufacturing validation to reduce upfront costs for potential customers.